



**FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO**

## **MESTRADO INTEGRADO EM MEDICINA**

---

**2011/2012**

Pedro Manuel Marques de Freitas

**Polyphenols and Neurodegenerative Diseases**

**Março, 2012**

**FMUP**



FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO

Pedro Manuel Marques de Freitas  
Polyphenols and Neurodegenerative Diseases

**Mestrado Integrado em Medicina**

**Área: Bioquímica**

**Trabalho efetuado sob a Orientação de:  
Doutora Maria da Conceição Costa Pinho Calhao**

**Trabalho organizado de acordo com as normas da revista:  
Nutritional Neuroscience**

**Março, 2012**

**FMUP**

Eu, PEDRO MANUEL MARQUES DE FREITAS, abaixo assinado, nº mecanográfico 010801044, estudante do 6º ano do Mestrado Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 21/03/2012

Assinatura: Pedro Manuel Marques de Freitas

Nome: Pedro Manuel Marques de Freitas

Endereço eletrónico: pedrommf@med.up.pt Telefone ou Telemóvel: 965706705

Número do Bilhete de Identidade: 12218013

Título da Monografia:

Polyphenols and Neurodegenerative Diseases

Orientador:

Doutora Maria da Conceição Costa Pinho Calhau

Ano de conclusão: 2012

Designação da área do projeto:

Bioquímica

É autorizada a reprodução integral desta Monografia para efeitos de investigação e de divulgação pedagógica, em programas e projetos coordenados pela FMUP.

Faculdade de Medicina da Universidade do Porto, 21/03/2012

Assinatura: Pedro Manuel Marques de Freitas

# **Polyphenols and Neurodegenerative Diseases**

Pedro Freitas

**From:** Department of Biochemistry, Faculty of Medicine, Porto University, Porto, Portugal.

**Correspondence:** Pedro Manuel Marques de Freitas

Department of Biochemistry, Faculty of Medicine, Porto University

Al. Prof. Hernâni Monteiro

4200-319 Porto, Portugal

Phone: +351225513624

Fax: +351225513624

E-mail: [pedrommf@med.up.pt](mailto:pedrommf@med.up.pt)

**Word count:** 6334

**Number of tables/figures:** 3

## **Abstract**

With the expansion of the aged population, the prevalence of age-associated disorders like Alzheimer's and Parkinson's disease is growing, as well as the economic burden of its care and treatment. In this light, the preventive and therapeutic benefits of dietary polyphenols may directly improve human life and healthcare costs. Polyphenols display the capacity to protect neurons against oxidative stress, an ability to suppress neuroinflammation, and the potential to promote memory, learning and cognition. The anti-aging and neuroprotective aptitude of these dietary-derived phytochemicals counteract the environment in which neurodegenerative diseases arise. And while the mechanisms by which these effects occur are yet to be fully understood, it is evident that further investigation may yield a potential use for polyphenols as nutritional and pharmacological interventions against specific age-associated diseases. The focus of this review is aimed at presenting the classification, bioavailability and metabolism of polyphenols, as well as the mechanisms of action underlying their neuroprotective features.

**Keywords:** Alzheimer, diet, inflammation, Parkinson, polyphenols.

## **Introduction**

Ageing is a highly complex process marked by succeeding events that promote alterations in the normal functioning of an individual organism over time.<sup>1</sup> The overall decline in function of entire organs or systems with subsequent vulnerability to oxidative and inflammatory insults, is known to play a key role in both ageing and the complex etiology of certain age-associated diseases such as Alzheimer's and Parkinson's disease.

The aim of this article is to give an overview on the dynamic capacity of polyphenols to protect the central nervous system, by exerting antioxidant activities, suppressing neuroinflammation, and improving cognitive function.

## **Polyphenols: classification, bioavailability and metabolism**

Polyphenols (i.e. several hydroxyl groups on aromatic rings) are secondary metabolites of plants, that were initially identified as the plant's defensive response against stress from ultraviolet radiation, pathogens, and physical damage.<sup>2</sup> They also contribute to their pigmentation, and are responsible for the astringency and bitterness of plant derived food and beverage.<sup>3</sup>

About 10,000 phenolic compounds of plant origin have been characterized, ranging from simple molecules to highly polymerized compounds. They can be broadly divided

into two categories, flavonoids and non-flavonoid polyphenols, depending on the number of phenol rings and the chemical groups that bind these rings to one another (Table 1).<sup>4</sup>

Flavonoids comprise the largest and most important single group of polyphenols. They are found ubiquitously in plants and dietary sources include fruits, vegetables, cereals, tea, wine and fruit juices.<sup>5</sup> Flavonoids consist of two aromatic carbon rings, benzopyran (A and C rings) and benzene (B ring), and may be divided into six subgroups based on the degree of oxidation of the C-ring, the hydroxylation pattern of the ring structure and the substitution of the 3-position.<sup>5</sup> The main dietary groups of flavonoids are (1) flavonols (e.g. kaempferol, quercetin), which are found in onions, leeks, and broccoli; (2) flavones (e.g. apigenin, luteolin), which are found in parsley and celery; (3) isoflavones (e.g. daidzein, genistein), which are mainly found in soy and soy products; (4) flavonones (e.g. hesperetin, naringenin), which are mainly found in citrus fruit and tomatoes; (5) flavan-3-ols (e.g. catechin, epicatechin, epigallocatechin, epigallocatechin gallate), which are abundant in green tea, red wine, and chocolate; and (6) anthocyanidins (e.g. pelargonidin, cyanidin, malvidin), whose sources include red wine and berry fruits.<sup>6</sup>

Among the non-flavonoid polyphenols there are 4 distinct groups: (1) phenolic acids (e.g. caffeic acid, gallic acid); (2) lignans (e.g. secoisolariciresinol); (3) stilbenes (e.g. resveratrol); and (4) curcuminoids (e.g. curcumin).

Two classes of phenolic acids can be distinguished: derivatives of benzoic acid and derivatives of cinnamic acid. The benzoic acid content of edible plants is generally very low, with the exception of certain red fruits, black radish, onions and tea leaves (gallic acid). The cinnamic acids are more common and consist chiefly of p-coumaric, caffeic,



ferulic and sinapic acids . Blueberries, kiwis, plums, cherries and apples possess the highest content of cinnamic acids, being caffeic acid the most abundant phenolic acid.<sup>5</sup>

Lignans are formed of 2 phenylpropane units. The richest dietary source is linseed, which contains secoisolariciresinol and low quantities of matairesinol. Lentils, triticale, wheat, garlic, asparagus, carrots, pears and prunes are minor sources of lignans.<sup>5</sup>

Stilbenes are molecules of two phenolic rings connected by an ethene molecule. Resveratrol is the main stilbene and can be found in grapes, red wine, berries, pistachios and peanuts. There are two isomeric forms of resveratrol, *cis*-resveratrol and the most biologically active *trans*-resveratrol (*trans*-3,4,5-trihydroxystilbene).<sup>7</sup>

Curcuminoids are major chemical components of turmeric, a commonly used spice derived from the rhizome of the plant *Curcuma longa*, used to give specific flavor and yellow color to Indian curries and in food preservation. Curcumins in turmeric include curcumin I (77%), demethoxycurcumin (curcumin II, 17%), and bisdemethoxycurcumin (curcumin III, 3%).<sup>8</sup>

Bioavailability of polyphenols varies widely from one compound to another, so it is important to realize that the polyphenols that are most common in the human diet are not necessarily the most active within the body. Chemical structure, which determines their rate and extent of intestinal absorption is the main factor responsible for their biological activities. Other variables, such as intestinal absorption, excretion of glucuronides toward the intestinal lumen, metabolism by the microflora, intestinal and hepatic metabolism, plasma kinetics, the nature of circulating metabolites, binding to albumin, cellular uptake, intracellular metabolism, accumulation in tissues, and biliary and urinary excretion are also very important, and should be integrated when determining polyphenols bioavailability and be considered in bioactivity research.<sup>5</sup>

Natural polyphenols occur in conjugated form, with one or more sugars, generally bound to the hydroxyl group. Glycosylation influences their physical, chemical, or biological properties, and determines their absorption by the small intestine, which is also affected by their molecular size, degree of polymerization (tannin formation), binding to proteins, or dietary fibers, and solubility.<sup>3</sup> Polyphenols present as aglycones can be absorbed from the small intestine, however most of them are present in the form of esters, glycosides, or polymers and are not easily absorbed in their natural form.<sup>9-11</sup> It is generally accepted that the breakdown of these conjugates to aglycones by acid hydrolysis in the stomach and by the microflora in the gut is required to produce the bioactive compounds that are readily bioavailable to the body.<sup>4</sup> However, relatively little is known about the ability of these aglycone forms to reach the target cells or what the influence of further metabolism in the body has on their spectra of biological activities.<sup>4</sup>

The intestinal absorption of polyphenols can be high, however the plasma concentration of any individual molecule only ranges from 0 to 4  $\mu\text{mol/L}$  after the consumption of 50 mg of aglycone equivalents.<sup>10</sup> Therefore, the maintenance of a high plasma concentration requires repeated ingestion over time. Measurement of the plasma antioxidant capacity suggests that more phenolic compounds are present, largely in the form of unknown metabolites, produced either in our tissues or by the colonic microflora.<sup>9-11</sup> The activities of microbial metabolites must be examined in further studies to determine active structures, available concentrations, and potential modulation of the capacity of the microflora to produce such metabolites.<sup>5</sup> Changes in the composition of the colonic microflora could explain the large interindividual variations in polyphenols bioavailability.<sup>9-11</sup>

The methods surveying the occurrence in food of the various types of polyphenols are not well-standardized, consequently only partial information is available on the quantities of polyphenols that are consumed daily throughout the world. Precise measurements have been done regarding flavonols, flavones, isoflavones, and phenolic acids. Consumption of flavonols has been estimated at  $\approx 20 - 25$  mg/d in the United States, Denmark, and Holland.<sup>12-14</sup> In Japan, an average dietary intake of  $30 - 40$  mg/d for isoflavones was determined.<sup>15-16</sup> The mean consumption of flavonones was  $28,3$  mg/d in Finland, in addition, anthocyanidin consumption was found to be  $82$  mg/d on average, reflecting the high consumption of berries that is customary in this country.<sup>5</sup> Consumption of soya in the Asian countries is  $\approx 10 - 35$  g/d, which is equivalent to a mean intake of  $25 - 40$  mg isoflavones/d.<sup>15-17</sup> In Spain the total consumption of catechins and proanthocyanidin dimers and trimers has been estimated at  $18 - 31$  mg/d, and the main sources are apples, pears, grapes, and red wine.<sup>5</sup> Consumption of hydroxycinnamic acids may vary highly according to coffee consumption. Some persons who drink several cups per day may ingest as much as  $500 - 800$  mg hydroxycinnamic acids/d, whereas subjects who do not drink coffee and also eat small quantities of fruit and vegetables do not ingest  $>25$  mg/d.<sup>5</sup> A German study estimated daily consumption of hydroxycinnamic acids and hydroxybenzoic acids at  $211$  and  $11$  mg/d, respectively. Caffeic acid intake alone was  $206$  mg/d, and the principal sources were coffee (which provides 92% of caffeic acid) and fruit and fruit juices combined (source of 59% of *p*-coumaric acid).<sup>18</sup>

The addition of the mean values of flavonols, flavanones, flavan-3-ols, and isoflavones intakes gives a total daily consumption of  $100 - 150$  mg in Western populations, to which must be added the considerably variable intake of hydroxycinnamic acids, anthocyanidines, and proanthocyanidines.<sup>5</sup> Flavonoids account

for two thirds of total dietary phenols, and phenolic acids account for the remaining third.<sup>9</sup> Finally, the total polyphenol intake probably reaches 1 g/d in people who eat several servings of fruit and vegetables per day.<sup>5</sup> The polyphenols that are most well absorbed in humans are isoflavones and gallic acid, followed by catechins, flavanones, and quercetin glucosides. The least well absorbed polyphenols are the proanthocyanidines, the galloylated tea catechins, and the anthocyanidins.<sup>10</sup>

Paramount importance for the relevance of food polyphenols in the protection of the aging brain is the ability of these compounds to cross the blood-brain barrier (BBB), which controls the entry of xenobiotics into the brain and the maintenance of the brain's microenvironment.<sup>19-21</sup> The BBB is formed by the endothelium of brain microvessels, under the inductive influence of associated cells, especially astrocytes.<sup>19-21</sup> Polyphenols penetration through the BBB is dependent on the degree of lipophilicity of each compound,<sup>22</sup> with less polar polyphenols or metabolites (i.e., O-methylated derivatives) capable of greater brain uptake than the more polar polyphenols and/or metabolites (i.e., sulfated and glucuronidated derivatives), and their interactions with specific efflux transporters expressed in the BBB, such as the multidrug resistance-associated proteins (MRPs).<sup>23</sup>

Several studies have indicated that the flavonones hesperetin, naringenin and their relevant *in vivo* metabolites, as well as some dietary anthocyanidins, cyanidin-3-rutinoside and pelargonidin-3-glucoside, are able to traverse the BBB.<sup>22-25</sup> Green tea catechins are brain permeable,<sup>26-27</sup> and, after oral administration, could be found in the rat brain as glucuronide and 3'-O-methyl epicatechin glucuronide.<sup>28</sup> Anthocyanidines have also been detected in the brain after oral administration,<sup>29-30</sup> with several anthocyanidines being identified in regions of rat brain after the animal were fed with

blueberries.<sup>31</sup> Curcumin is highly lipophilic and crosses the BBB to reach the brain, but its bioavailability is very low, since the drug is rapidly metabolized by conjugation.<sup>32</sup>

Although it is clear that polyphenols can reach the brain, the precise brain distribution of polyphenols after oral administration is less well studied. It has been reported that anthocyanidins were detected in the cerebellum, cortex, hippocampus, and striatum of blueberry-supplemented rats,<sup>33</sup> and several anthocyanidins have been identified in various regions of the rat<sup>34</sup> and pig<sup>35-36</sup> brain after berry supplementation. Such flavonoid localization has been correlated with increased cognitive performance, suggesting a central neuroprotective role for these compounds.<sup>31</sup>

### **Oxidative stress, inflammation and neurodegenerative diseases**

There is a common character for age-related neurodegenerative diseases: all of them are connected with oxidative stress-induced neuronal apoptosis. Oxidative stress (OS) experienced during normal metabolism, and the accumulated damage to important cellular components and structures, is one of the primary contributors to the ageing process and senescence at the cellular level.<sup>37</sup>

Free radicals can be defined as molecules or molecular fragments containing one or more unpaired electrons in atomic or molecular orbitals. These unpaired electrons give a considerable degree of reactivity to free radicals. Reactive oxygen species (ROS) (hydrogen peroxide -  $\text{H}_2\text{O}_2$ , or superoxide anion -  $\text{O}_2^-$ ), as well as reactive nitrogen species, are products of normal cellular metabolism, mainly energy production processes like the electron transport chain in mitochondria, and play a dual role in both

deleterious and beneficial effects, especially in numerous signal transduction mechanisms. OS results from the shift toward ROS production in the equilibrium between ROS generation and the antioxidant defense system, which includes enzymes such as superoxide dismutase, catalase, glutathione peroxidase, as well as low molecular weight compounds, such as glutathione, generally found at levels sufficient enough to defend cells from oxidative insult.<sup>38</sup> The high metabolic rate, the low concentrations of glutathione and catalase, and the high proportion of polyunsaturated fatty acids, make brain tissue particularly susceptible to oxidative damage.<sup>39</sup>

Mounting evidence suggests that increased OS occurs in the aging brain, including reductions in redox active iron,<sup>40-42</sup> as well as increases in Bcl-2, membrane lipid peroxidation, and cellular hydrogen peroxide.<sup>42</sup> Additionally, there is significant lipofuscin accumulation,<sup>38</sup> along with alterations in membrane lipids.<sup>43</sup> The consequences of these increases in OS at several levels may result in disruption of calcium homeostasis, alterations in cellular signaling cascades, and changes in gene expression,<sup>44-48</sup> which combine to contribute to the increased vulnerability to OS seen in the ageing population,<sup>49</sup> and which is elevated in neurodegenerative diseases, such as Alzheimer's disease (AD)<sup>50-51</sup> and Parkinson's disease (PD).<sup>52-54</sup>

AD is the most common type of dementia in the elderly, with an incidence of about 2% in the industrialized countries, affecting 15 – 20 million people worldwide.<sup>55</sup> It is associated with progressive memory loss and cognitive impairment, due to neurodegeneration. Besides genetic factors, which comprise around 7% of familial AD patients, epigenetic and environmental factors are known to play an important role in the onset of sporadic AD.<sup>55</sup>

Common pathological hallmarks for AD are the accumulation of amyloid plaques and neurofibrillary tangles in the neocortex.<sup>56</sup> Amyloid beta (A $\beta$ ), a peptide of 39 – 43 amino acids, is the main constituent of amyloid plaques, and is the product of the aberrant fragmentation of a membrane protein, the Amyloid Precursor Protein (APP).<sup>57-58</sup> APP can be alternatively processed by cleavage by  $\alpha$ -secretase (a harmless process whose physiological role has not been clarified yet), or by the sequential proteolysis carried out by  $\beta$ -secretase and  $\gamma$ -secretase, leading to the release of A $\beta$  that can then be aggregated in the oligomeric form.<sup>2,55</sup> The A $\beta$  peptide has been proven to generate free radicals through the production of hydrogen peroxide, through metal ion reduction (especially Zn, Cu and Fe), with concomitant release of thiobarbituric acid-reactive substances (TBARS), a process probably mediated by formation of hydroxyl radicals with concomitant stimulating of inflammatory cells.<sup>59</sup> Oligomeric A $\beta$  can confer oxidative insult to neurons and glial cells and initiate changes in synaptic plasticity, events occurring long before their deposition to form amyloid plaques.<sup>60</sup> Furthermore, in the AD brain, tau-protein, a microtubule-associated protein becomes hyperphosphorylated and oxidized, forming intracellular proteinaceous deposits, the neurofibrillary tangles.<sup>61</sup>

Oligomeric A $\beta$  is able to confer specific action on the N-methyl-D-aspartic acid (NMDA) receptors, which not only regulate synaptic plasticity, and memory function, but up on their activation are coupled with ROS production.<sup>62-66</sup> Thus, NADPH oxidase may be common in NMDA- and A $\beta$ -induced ROS production, and activation of signaling pathways including protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), which in turn, lead to the activation of cytosolic phospholipase A2 and release of arachidonic acid.<sup>66</sup> Arachidonic acid not only is a precursor for synthesis of prostaglandins, but is also known to serve as a retrograde transmitter in regulating

synaptic plasticity.<sup>67</sup> Intracellular A $\beta$  may target cytoplasmic signaling pathways and impair mitochondrial function.<sup>68</sup> A $\beta$ -mediated ROS production is also linked to increased inflammatory responses, including increased production of cytokines, nitric oxide, and eicosanoids.<sup>69-71</sup>

PD is a chronic progressive neurodegenerative movement disorder characterized by a profound and selective loss of dopaminergic neurons in the substantia nigra pars compacta, and it affects approximately 1% of the population over the age of 50.<sup>54,72</sup> Clinical manifestations of PD include motor impairment involving resting tremor, a slowing of physical movement (bradykinesia), postural instability, gait difficulty, and rigidity.

The most probable origin of the etiology of dopaminergic neuronal demise is a combination of genetic susceptibilities and environmental factors, including heavy metals and herbicides.<sup>73-74</sup> Oxidative stress has been widely believed to be an important pathogenetic mechanism of neuronal apoptosis in PD.<sup>75</sup> The majority of PD cases are sporadic (90 – 95%), while familial cases account for 5 – 10% of PD.<sup>76</sup>

One of the pathological hallmarks of PD is the presence of intracellular inclusions called Lewy bodies that consist of aggregates of the presynaptic soluble protein called  $\alpha$ -synuclein.<sup>77-78</sup> The toxic effects of  $\alpha$ -synuclein include impaired endoplasmic reticulum, Golgi fragmentation, sequestration of anti-apoptotic proteins into aggregates, and the formation of pores on cellular membranes.<sup>79</sup> The onset of PD is accompanied by the dramatic depletion of levels of glutathione in substantia nigra, resulting in a selective decrease in mitochondrial complex I activity (a major hallmark of PD) and a marked reduction in overall mitochondrial function.<sup>80</sup> The harm to mitochondrial



complex I causes  $\alpha$ -synuclein aggregation, which contributes to the death of dopamine neurons, leading to a dopamine deficit in the striatum.

The features of enhanced oxidative stress linked with PD are supported by postmortem studies, and by studies demonstrating the capacity of oxidative stress to induce nigral cell degeneration.<sup>81</sup> In addition, other important factors, involving inflammation, toxic action of nitric oxide, defects in protein clearance, and mitochondrial dysfunction all contribute to the etiology of PD.<sup>82</sup>

Iron content alterations have been described in the brains of PD and AD patients, which may be caused to a large extent, by endogenous dysregulation of iron uptake, transport, distribution, and storage.<sup>83-86</sup> Iron is one of the most essential transition metals involved in the formation of ROS, owing to its interaction with hydrogen peroxide through Fenton chemistry and generation of the aggressively reactive hydroxyl radical. Accumulation of iron, specifically in the substantia nigra pars compacta, is one cardinal feature of PD, and is considered to be a major contributor to OS.<sup>87</sup> Analysis of AD brains indicates iron accumulation within specific brain regions, displaying selective vulnerability to neurodegeneration, such as the hippocampus and cerebral cortex.<sup>88-89</sup> Damage to brain cells in Parkinson's, Alzheimer's and other neurodegenerative diseases seems to result from the combination of a number of damaging factors including excessive inflammation and increased levels of iron, both of which lead to increased free radical production, exhaust the brain's supply of protective antioxidants and trigger the production of certain proteins, such as A $\beta$ .

## **Polyphenols display neuroprotective effects**

One of the most important aspects of current polyphenol research is the focus on the neuroprotective capacity that is a characteristic feature of this broad family of compounds. There is increased interest in uncovering efficient antioxidants to reduce the risk of AD, PD, and other neurodegenerative disorders, since current therapeutic approaches are merely symptomatic, without any disease-modifying activity. Because many diseases of ageing can be directly linked to repeated oxidative stress and chronic inflammation,<sup>90</sup> therapies that can diminish such effects have become an important tool in seeking more effective treatments for diseases such as Alzheimer's and Parkinson's.<sup>53,91</sup>

Continuing research highlights the dynamic capacity of polyphenols to protect against age-associated disorders through a variety of important mechanisms. The chemical antioxidant activity of polyphenols is correlated with the number of hydroxyl groups present on the aromatic A and B rings, and with the presence of a C2-C3 double bond, the most active ones containing between 3 and 6 hydroxyl groups.<sup>52</sup> The antioxidant mechanism is based on the donation of a hydrogen and the formation of a phenoxyl radical that undergoes stabilization either by release of a further hydrogen, or by reaction with another radical.<sup>3</sup> In general, polyphenols have the capacity to chelate metal ions and to quench free radical species.<sup>53</sup> The ability of flavones and flavan-3-ol polyphenols to chelate redox-active transition metal ions, such as iron or copper, depends on the presence of their carboxylic and hydroxylic groups and may contribute to their antioxidant activity, because it prevents metals from catalyzing free radical formation.<sup>54</sup>

Green tea is an extremely popular drink in eastern countries, and green tea polyphenols known as catechins, are natural plant flavonoids found in the tea leaves. The major tea catechins include, epicatechin (EC), epigallocatechin (EGC), EC gallate (ECG), and EGC gallate (EGCG).<sup>92</sup> Other compounds in green tea are the flavonols (quercetin, kaempferol, and rutin), caffeine, phenolic acids, and theanine.<sup>93</sup> Catechins are especially concentrated in green tea, which account for 30 – 40% of the dry weight of the leaves.<sup>94-95</sup> All four tea catechins have been demonstrated to be potent antioxidants, resulting from their direct oxygen and nitrogen species scavenging properties, induction of endogenous antioxidant enzymes, and the capacity to bind and chelate excess of divalent metals, such as iron and copper.<sup>96-97</sup> The rank order of antioxidant abilities of green tea components is EGCG>ECG>EGC>EC.<sup>98</sup> Catechins are well absorbed after oral administration, and are biotransformed in the liver to their conjugated metabolites, i.e., glucuronidated, methylated, sulfated derivatives.<sup>1</sup> By simply drinking green tea, polyphenols can cross the BBB and have neuroprotective effects.<sup>99</sup>

Nutritional studies demonstrated that a consumption of green tea could have a beneficial role in reducing the risk of PD.<sup>100</sup> The mechanisms underlying this beneficial role were the capacity of EGCG to act as an iron chelator,<sup>101</sup> and increase the activity of two major antioxidant enzymes, superoxide dismutase and catalase, further helping to decrease free radical damage.<sup>102</sup> EGCG has also been shown to competitively inhibit the uptake by the presynaptic or vesicular transporters of metabolites from the neurotoxin MPTP (*N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).<sup>103</sup> This competition could protect dopaminergic neurons against MPTP induced injury.<sup>104</sup>

In AD, EGCG has been reported to interfere with an early step in the amyloid formation cascade by binding directly to the natively unfolded  $\alpha$ -synuclein and A $\beta$

polypeptides, thus inhibiting their fibrillogenesis and redirecting them into an alternative “off pathway” before they become toxic.<sup>105</sup> EGCG has recently been found to convert large, mature  $\alpha$ -synuclein and A $\beta$  fibrils into smaller, amorphous non-toxic protein aggregates.<sup>106</sup> In addition, EGCG exerts neuroprotection by modulating intracellular signaling pathways such as MAPK,<sup>107</sup> PKC,<sup>108-110</sup> and PI-3K/Akt<sup>111</sup> which will be discussed later in this review, and inhibit the activation of nuclear factor kappaB<sup>112</sup> (NF- $\kappa$ B) and pro-apoptotic pathways.<sup>113</sup>

Several studies using dietary supplements with either spinach, strawberries, or blueberries extracts have been reported to reduce some neurological deficits in aged animals (Morris water maze performance).<sup>114-118</sup> In addition, blueberries supplementation was also effective in reversing cognitive declines in object recognition.<sup>119</sup> Catechin, epicatechin, and anthocyanidins are the main polyphenols present in blueberries, and there is a significant positive correlation between their serum content and postprandial antioxidant status.<sup>120</sup> Aged rats with blueberries supplemented diet had significantly lower levels of NF- $\kappa$ B than aged control diet rats,<sup>119</sup> revealing that the neuroprotection conceded might involve more than the blueberries extract antioxidant actions. Blueberries extract supplementation could also reduce the volume of infarction in the cerebral cortex, and increase the post-stroke locomotor activity induced by ischemia/reperfusion,<sup>118</sup> as well as protect against neuronal loss in the CA1 and CA2 regions of the hippocampus after cerebral ischemia.<sup>121</sup> Additionally, blueberries supplemented APP/PS1 mice exhibited greater levels of hippocampal extracellular signal regulated kinase (ERK), as well as striatal and hippocampal PKC $\alpha$ , when compared with transgenic mice maintained on a control diet.<sup>122</sup>

Resveratrol is the main non-flavonoid polyphenol found in grapes and red wine, and it has been reported to possess antioxidant, anti-inflammatory, antimutagenic, and

anticarcinogenic effects,<sup>123-124</sup> as well as a beneficial effect against AD pathology by promoting anti-amyloidogenic mechanisms.<sup>100</sup> Several epidemiological studies indicate that a moderate consumption of wine is associated with a lower incidence of AD.<sup>125-127</sup> Resveratrol not only possesses the capacity to directly scavenge free radical species, but also regulates the cytotoxic effects of A $\beta$  oligomers and fibrils via phosphorylation of PKC, which activates the transmembrane protein  $\alpha$ -secretase.<sup>128-129</sup>  $\alpha$ -secretase catalyzes the formation of a soluble, non-amyloidogenic (non-plaque forming) protein from APP, and thus does not allow for the formation of neuritic plaques. Modulation of NF- $\kappa$ B activity, or NF- $\kappa$ B/SIRT1 pathway could also be implicated in the neuroprotective effect of resveratrol, since activation of SIRT1 by resveratrol inhibits NF- $\kappa$ B signaling by promoting deacetylation of lys310 of RelA/p65<sup>130</sup>, thereby protecting cells against the A $\beta$  peptide.<sup>131-132</sup>

Genistein, the most active component of soy isoflavone, is a phytoestrogen that is capable of crossing the BBB,<sup>133</sup> manifesting potent antioxidative properties,<sup>134-135</sup> and neuroprotective activity.<sup>59</sup> Genistein has been shown to protect neurons from A $\beta$ -induced damages largely via an estrogen receptor mediated pathway, as well as by its antioxidative properties.<sup>59</sup>

Curcumin has been used for centuries in Asia as a food additive and a traditional herbal medicine, and it has been revealed that besides its potent antioxidative, and anti-inflammatory properties, it also exhibits anti-amyloidogenic effects.<sup>136</sup> Epidemiological studies have raised the possibility that the properties of this molecule are responsible for the significantly reduced (4.4 fold) prevalence of AD in India compared to the United States of America.<sup>137</sup> These observations could be explained by the ability of curcumin to reduce IL-1 $\beta$ ,<sup>138</sup> a proinflammatory cytokine, inhibit  $\beta$ -secretase and A $\beta$  aggregation,<sup>7,139</sup> and bind to the redox-active metals iron and copper.<sup>140</sup> The

neuroprotective effects of curcumin relevant to PD are likely to be associated with its antioxidant and anti-inflammatory properties.<sup>141-142</sup> Acute oral administration of curcumin results in poor bioavailability due to its rapid conversion to glucuronides, suggesting that very small doses of curcumin are necessary for its neuroprotective effect.<sup>2</sup> In addition, it is worth noting that excessive application of curcumin may produce pro-oxidative effects.<sup>143</sup>

The flavonoid-rich ginkgo biloba has been used for 5000 years in traditional Chinese medicine. EGb 761 is a standardized extract of ginkgo biloba, whose flavonoid content is composed of quercetin, kaempferol, and isorhamnetin. Several studies have highlighted the potential of EGb 761 and its constituents to prevent lipid oxidation,<sup>144</sup> and to act as antioxidants and free radical scavengers.<sup>145-146</sup> Ginkgo biloba also exerts a combination of anti-amyloidogenic, and anti-apoptotic effects particularly in connection with age related dementias and AD.<sup>147-149</sup> EGb 761 is able to inhibit A $\beta$  fibrils formation due to its iron chelating properties,<sup>147,150</sup> and is able to rescue primary hippocampal neurons and PC12 cells against the toxicity of the A $\beta$  peptide.<sup>150-151</sup>

### **Polyphenols improve memory**

With ageing, neuronal populations and synaptic connections are lost over time, resulting in diminished efficiency in the processing and storage of sensory information, however, emerging evidence suggests that polyphenols are able to induce improvements in memory acquisition, consolidation, storage, and retrieval. There is strong evidence that flavonoid intake is associated with better cognitive evolution, i.e. the preservation of cognitive performance with ageing.<sup>152</sup> Furthermore, flavonoids found in fruits and

fruit juices (most notably flavan-3-ols, flavanones, and anthocyanins) have the capacity to improve memory.<sup>30,153-155</sup> A number of animal intervention studies, using diets containing between 1 and 2% (w/w) freeze-dried fruit/fruit juice, have indicated that grape, pomegranate, strawberry, and blueberry, as well as pure flavonoids (epicatechin and quercetin), are capable of affecting several aspects of memory and learning, notably rapid<sup>156</sup> and slow<sup>157-160</sup> memory acquisition, short-term working memory,<sup>153,161-164</sup> long-term reference memory,<sup>165</sup> reversal learning,<sup>156,161</sup> and memory retention/retrieval.<sup>166</sup> For example, fruits such as strawberry, blueberry, and blackberry (all rich in anthocyanidins and flavan-3-ols) have been shown to be beneficial in retarding functional, age-related central nervous system and cognitive behavioral deficits.<sup>157,167-168</sup> There is also extensive evidence that blueberries are effective at reversing age-related deficits in spatial working memory.<sup>153,163,165,168-173</sup>

The ability of polyphenols to reverse age-related declines in memory, relies on their potential to interact with the cellular and molecular architecture of the brain responsible for memory. In general, the short-term storage of both implicit and explicit memory involves functional changes in the strength of pre-existing synaptic connections, whilst their long term storage requires the synthesis of new protein and the growth of new connections.<sup>5</sup> The capacity of polyphenols to interact with, and effectively modify the pathways within neurons and synapses leading to changes in the efficiency of *de novo* protein synthesis, will allow for the likelihood to affect the process of memory.<sup>5</sup>

Long-term potentiation (LTP) is widely considered to be one of the major mechanisms by which the brain learns and maintains memories.<sup>174-175</sup> It refers to a persistent increase in the chemical strength of a synapse, and is known to contribute to “synaptic plasticity” or the increased strength of the connection between two neurons, a process thought to underlie memory.<sup>176-177</sup> Various signaling pathways have been linked

with the control of *de novo* protein synthesis in the context of LTP, synaptic plasticity and memory: (1) cAMP-dependent protein kinase (protein kinase A);<sup>178</sup> (2) protein kinase B (PKBAkt);<sup>179</sup> (3) PKC;<sup>180</sup> (4) calcium-calmodulin kinase (CaMK);<sup>181</sup> and (5) ERK.<sup>182-183</sup> All five pathways converge to signal to the cAMP-response element-binding protein (CREB), a transcription factor which binds to the promoter regions of many genes associated with synapse re-modeling, synaptic plasticity and memory (Figure 1).<sup>185-185</sup> The importance of CREB activation in the induction of long-lasting changes in synaptic plasticity and memory is highlighted by studies which show that disruption of CREB activity specifically blocks the formation of long-term memory,<sup>186</sup> whereas agents that increase the amount or activity of CREB accelerate the process.<sup>187</sup> Furthermore, CREB is known to be a critical transcription factor linking the actions of neurotrophins, such as BDNF, to neuronal survival, differentiation, and synaptic function.<sup>188-189</sup> BDNF belongs to the neurotrophin family of growth factors and affects the survival and function of neurons in the central nervous system. It's secretion from neurons is under activity dependent control and is crucial for the formation of appropriate synaptic connections during development, and for learning and memory in adults.<sup>190</sup> Decreases in BDNF and pro-BDNF have been reported in AD,<sup>191-192</sup> and the importance of pro-BDNF has been emphasized by the finding that a polymorphism that replaces valine for methionine at position 66 of the pro-domain is associated with memory defects and abnormal hippocampal function in humans.<sup>193</sup> Ultimately, CREB activation and neurotrophyn synthesis are able to induce synaptic plasticity, and represents a vital stage in converting brief afferent signals into long lasting memory.<sup>5</sup> The increase in synaptic receptor, and neuronal spine density and morphology are hallmarks of synaptic plasticity ,<sup>194-195</sup> and constitute integral events in LTP.<sup>5</sup>



Flavonoids through the interactions within MAPK pathways, such as the ERK pathway are believed to influence memory,<sup>196</sup> since ERK is associated with pro-survival and pro-neurotrophin signaling through the activation of CREB.<sup>197-199</sup> Fisetin, a flavonoid found in strawberries, has been shown to improve LTP and to enhance object recognition in mice by a mechanism dependent on the activation of ERK and CREB.<sup>200</sup> Similarly, the flavan-3-ol (-)epicatechin induces both ERK 1/2 and CREB activation in cortical neurons and subsequently increases CREB regulated gene expression,<sup>201</sup> whilst nanomolar concentrations of quercetin are effective at enhancing CREB activation.<sup>202</sup> The citrus flavanone hesperetin is also capable of activating ERK 1/2 signaling in cortical neurons,<sup>203</sup> and EGCG is capable of restoring both PKC and ERK 1/2 activities in 6-hydroxydopamine treated and serum deprived neurons.<sup>109,204</sup> These effects on the ERK pathway are highly concentration-dependent, with high affinity receptor agonist-like actions at low concentrations, and direct enzyme inhibition at high concentrations.<sup>205-206</sup> In addition, the finding that anthocyanidins and flavan-3-ols appear in the hippocampus following blueberry supplementation may indicate that changes in memory are linked directly to flavonoids and their action on the ERK-CREB-BDNF pathway.<sup>207</sup>

Another mechanism that may exert beneficial effects on memory consists on the ability of flavonoids to activate the Akt/PKB pathway, which also has the potential to activate CREB. Hesperetin can activate the Akt/PKB pathway, as well as inhibit pro-apoptotic proteins such as ASK1, Bad, caspase-9, and caspase-3 in cortical neurons.<sup>203</sup>

Flavonoid-induced activation of CREB and enhancement of BDNF expression in neurons will ultimately lead to the activation of PI3 kinase/Akt signaling pathway *via* the binding of BDNF to pre- or post-synaptic TrkB receptors.<sup>208</sup> These events trigger the activation of the mTOR pathway and the increased translation of specific mRNA subpopulations,<sup>209</sup> including the activity-regulated cytoskeletal-associated protein

(Arc/Arg3.1). Arc/Arg3.1 expression, which is under regulatory control of both BDNF<sup>210</sup> and ERK signaling,<sup>211</sup> has been shown to facilitate changes in synaptic strength, and stimulate the growth of small dendritic spines into large mushroom-shaped spines through a mechanism dependent on actin polymerization.<sup>212</sup> In support of this, dietary supplementation with blueberries has been shown to increase hippocampal Arc/Arg3.1,<sup>4</sup> and specific flavan-3-ols have been shown capable of inducing neuronal dendrite outgrowth.<sup>109</sup> Furthermore, nobiletin, a poly-methoxylated flavone found in citrus peel, also induces neurite outgrowth<sup>213</sup> and synaptic transmission<sup>214</sup> *via* its ability to interact directly with MAPK and PKA signaling pathways.<sup>215</sup>

Flavonoid-rich foods may also influence memory by improving cerebral blood flow (CBF), which is decreased in patients with dementia<sup>216-217</sup> and is significantly lower in patients with AD.<sup>218</sup> Such vascular effects seem to be mediated by flavonoids potential to induce nitric oxide production in the endothelium, along with rapid vasodilatation leading to improved peripheral blood flow.<sup>219-220</sup> Increased cerebrovascular function is known to facilitate adult neurogenesis in the hippocampus,<sup>221</sup> with new hippocampal cells appearing clustered near blood vessels, which proliferate in response to vascular growth factors.<sup>222</sup> In support of this, flavonol-rich foods have been shown to cause significantly increased CBF in human subjects, one to two hours postintervention,<sup>223-224</sup> and an increase in CBF through the middle cerebral artery has been reported after the consumption of flavan-3-ol-rich cocoa using trans-cranial Doppler ultrasound.<sup>224</sup>

## **Polyphenols inhibit neuroinflammation**

Sustained neuroinflammatory processes may contribute to the cascade of events culminating in the progressive neuronal damage observed in many neurodegenerative disorders, most notably AD and PD,<sup>225-226</sup> and also with neuronal injury associated with stroke.<sup>227</sup> As such, the use of non-steroidal anti-inflammatory drugs, like ibuprofen, has been proposed to delay or even prevent the onset of such neurodegenerative disorders,<sup>228-229</sup> and epidemiological studies have indicated that the risk for developing AD was reduced in regular users of anti-inflammatory drugs.<sup>230</sup> Glial cells mediate the endogenous immune system within the microenvironment of the CNS, and their activation which increases in the normal ageing brain, is the hallmark of inflammation in the brain.<sup>231-232</sup> Activated microglia produce proinflammatory molecules, such as cytokines (IL-1, IL-6, TNF- $\alpha$ ), growth factors, and complement proteins, that in turn activate other cells to produce additional signaling molecules that further activate microglia in a positive feedback loop to perpetuate and amplify the inflammatory signaling cascade.<sup>233-235</sup>

There is a growing body of evidence to suggest that flavonoids and flavonoid-rich foods may be capable of counteracting such neuronal injury, thereby delaying the progression of these diseases.<sup>22,223,236-237</sup> To date, evidence relating to the inhibition of neuroinflammation by flavonoids indicate that they may act through, (1) an inhibitory role on the release of cytokines, such as IL-1 $\beta$  and TNF- $\alpha$ , from activated glia; (2) an inhibitory action against iNOS induction and subsequent nitric oxide production in response to glial activation; (3) an ability to inhibit the activation of NADPH oxidase and subsequent ROS generation in activated glia; and (4) a capacity to down-regulate

the activity of pro-inflammatory transcription factors such as NF- $\kappa$ B (Figure 2).<sup>238</sup> Furthermore, the potential to influence these events appear to be mediated by their influences on a number of glial and neuronal signaling pathways , such as the MAPK cascade.<sup>238</sup>

EGCG has been shown to attenuate neurodegeneration induced by the parkinsonian toxin 6-hydroxydopamine<sup>239</sup> and MPTP,<sup>240</sup> and hippocampal injury induced by transient global ischemia.<sup>241</sup> In addition, EGCG has been noted to interact with and modulate signaling pathways involved in neuroprotection, notably PKC and PI3-kinase.<sup>242-245</sup> *In vitro* studies have also indicated that flavonoids commonly found in oranges, berries, apples, and grapes, might act to prevent PD pathology because of their ability to prevent the formation of the endogenous neurotoxin 5-S-cysteinyl dopamine.<sup>246-249</sup> It has been shown that aged male Fischer 344 rats fed a blueberries supplemented diet showed reductions of age-induced increases in NF- $\kappa$ B expression, compared to those of aged nonsupplemented controls in the frontal cortex, hippocampus, and the striatum.<sup>119</sup>

The citrus flavanone naringenin has been found to be highly effective at reducing lipopolysaccharide/interferon- $\gamma$ -induced glial-cell activation and resulting neuronal injury, via inhibition of p38 and signal transducers and activators of transcription family-1, and a reduction in inducible nitric oxide synthase expression.<sup>249</sup> Other flavonoids have been shown to partially alleviate neuroinflammation through the inhibition of TNF- $\alpha$  production.<sup>250</sup> Flavonoids present in blueberries have also been shown to inhibit NO $\cdot$ , IL-1 $\beta$ , and TNF- $\alpha$  production in microglia cells,<sup>251</sup> while the flavonol quercetin<sup>252</sup> and the flavan-3-ols catechin and EGCG<sup>253</sup> have all been shown to attenuate microglia- and/or astrocyte-mediated neuroinflammation.

It should be mentioned that much of the existing *in vitro* data has utilized non-physiological concentrations of polyphenols, making it difficult to extrapolate these results to the *in vivo* scenario, however, *in vivo* evidence and select *in vitro* data have clearly indicated a potential for polyphenols to inhibit neuroinflammation and the neurodegeneration associated with it.<sup>238</sup>

## Conclusion

The substantial number of naturally occurring dietary polyphenols represent an emerging and promising tool in the prevention and treatment of neurodegenerative diseases such as AD and PD, as well as the deleterious effects of ageing. Polyphenols have often been generically referred to as “antioxidants” for their ability to react with and quench ROS produced during metabolic processes, however, the emerging view is that polyphenols can exert beneficial effects on cells not only through their antioxidant potential but also through an ability to suppress neuroinflammation, and the potential to promote memory, learning, and cognitive function.

The beneficial effects of polyphenols may prove to be a valuable asset in the quest to develop a new generation of drugs capable of counteracting neuroinflammation and associated neurodegenerative diseases, however, the research in this field is still incomplete. Many questions are still unanswered, especially regarding the transfer of the findings of the *in vitro* studies to the *in vivo* application, furthermore, to date there is not enough data to clearly associate flavonoid consumption with improvements in neurological health.<sup>254</sup> A first point of attention is that the bioavailability of the various food polyphenols is not yet completely known, and can be different for the same

molecule depending on its source and on food preparation, indeed, the quantity of polyphenols found in the plasma represents only a small percentage of the intake.<sup>255</sup> In addition, *in vitro* studies on the biological activity of polyphenols use the original molecule instead of the *in vivo* metabolites produced upon digestion, whose biological activities may differ from the parent compounds. Also, the side effects of polyphenols must be better understood since they display a biphasic behavior, acting as prooxidants at high concentrations, with inhibition of enzymes responsible for cell survival or activation of enzymes leading to cell death.<sup>256</sup>

For the obtention of a causal relationship between the consumption of polyphenols and their behavioral outcomes, future intervention studies will be required to utilize better-characterized intervention materials, more appropriate controls, and more rigorous clinical outcomes. For example, it would be highly advantageous to directly link behavioral responses to changes in hippocampal volume and density, changes in neural stem cell and progenitor cell populations, molecular changes related to synaptic plasticity, and alterations in CBF using MRI and fMRI techniques.<sup>254</sup> Functional MRI measures may be used to assess changes in blood flow that underlie improved cognitive functioning as a result of polyphenol supplementation.<sup>254</sup>

Despite the need for these additional studies, the ability of polyphenols to activate the CREB pathway in addition to their antioxidant and anti-inflammatory properties, establish them as potential precursor molecules in the quest to develop a new generation of drugs capable of counteracting and perhaps even reversing age-related losses in cognitive performance. Additionally, nutritional interventions may be designed to prevent or delay the age-related neurodegenerative diseases.

## **Acknowledgements**

I would like to thank Maria Conceição Costa Pinho Calhau, PhD for all her help, time and patience.

## References

1. Wagner W, Bork S, Horn P, Krunić D, Walenda T, Diehlmann A, et al. Aging and replicative senescence have related effects on human stem and progenitor cells. *PLoS One*. 2004;6:e5846.
2. Ferguson LR. Role of plant polyphenols in genomic stability. *Mutations Research*. 2001;475:89-111.
3. Roosi L, Mazzitelli S, Arciello M, Capo CR, Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. *Neurochem Res*. 2008;33:2390-400.
4. Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. *J Agric Food Chem*. 2008;56:4855-73.
5. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. *Am J Clin Nutr*. 2004;79:727-47.
6. Spencer JPE. The impact of flavonoids on memory: physiological and molecular considerations. *Chem Soc Rev*. 2009;38:1155-61.
7. Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. *CNS Neurosci Ther*. 2008;14:234-47.
8. Belkacemi A, Doggui S, Dao L, Ramassamy C. Challenges associated with curcumin therapy in Alzheimer disease. *Expert Rev Mol Med*. 2011;13:e34.
9. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr*. 2000;130 Suppl:S2073-85.
10. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*. 2005;81 Suppl:S230-42.
11. Rio DD, Borges G, Crozier A. Berry flavonoids and phenolics: bioavailability and evidence of protective effects. *Brit J Nutr*. 2010;104 Suppl:S67-90.
12. Sampson L, Rimm E, Hollman PC, de Vries JH, Katan MB. Flavonol and flavone intakes in US health professionals. *J Am Diet Assoc*. 2002;102:1414-20.
13. Justesen U, Knuthsen P, Leth T. Determination of plant polyphenols in Danish foodstuffs by HPLC-UV and LC-MS detection. *Cancer Lett*. 1997;114:165-7.
14. Hertog MGL, Hollman PCH, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. *Nutr Cancer*. 1993;20:21-9.
15. Kimura M, Arai Y, Shimoi K, Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. *J Epidemiol*. 1998;8:168-75.
16. Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, Nakayama T, Wada M, Ohno Y. Dietary intake and sources of isoflavones among Japanese. *Nutr Cancer*. 1999;33:139-45.
17. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hämäläinen E, Hasegawa T, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming traditional Japanese diet. *Am J Clin Nutr*. 1991;54:1093-100.
18. Radtke J, Linseisen J, Wolfram G. Phenolic acid intake of adults in a Bavarian subgroup of the national food consumption survey. *Z Ernährungswiss*. 1998;37:190-7.
19. Abbott NJ. Astrocyte – endothelial interactions and blood – brain barrier permeability. *J Anat*. 2002;200:629-38.
20. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in situ model of the blood-brain barrier. *Free Radic Biol Med*. 2004;36:592-604.
21. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: *in vitro* studies. *J Neurochem*. 2003;85:180-92.



22. Kavvadias D, Sand P, Youdim KA, Qaiser MZ, Rice-Evans C, Baur L. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. *Brit J Pharmacol*. 2004;142:811-20.
23. Abbot NJ, Rönnebeck L, Hannsson E. Astrocyte-endothelial interactions at the blood-brain barrier. *Nat Rev Neurosci*. 2006;7:41-53.
24. Youdim KA, Shukitt-Hale B, Joseph JA. Flavonoids and the brain: interactions at the blood – brain barrier and their physiological effects on the central nervous system. *Free Radic Biol*. 2004;37:1683-93.
25. Mandel S, Amit T, Reznichenko L. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative diseases. *Mool Nutr Food Res*. 2006;50:229-34.
26. Abd El Monhsen MM, Kuhnle G, Rechner AR. Uptake and metabolism of epicatechin and its access to brain after oral ingestion. *Free Radic Biol Med*. 2002;33:1693-702.
27. Faria A, Pestana D, Teixeira D, Courad PO, Romero I, Weksler B, et al. Insight into the putative catechin and epicatechin transport across blood-brain barrier. *Food Funct*. 2011;2:39-44.
28. Talavera S, Felgines C, Texier O, Besson C, Gil-Izquierdo A, Lamaison JL, Remesy C. Anthocyanin metabolism in rats and their distribution to digestive area, kidney, and brain. *J Agric Food Chem*. 2005;53:3902-8.
29. El Mohsen MA, Marks J, Kuhnle G, Moore K, Debnam E, Kaila SS, et al. Absorption, tissue distribution and excretion of pelargonidin and its metabolites following oral administration to rats. *Br J Nutr*. 2006;95:51-8.
30. Andres-Lacueva C, Shukitt-Hale B, Galli RL, Jauregui O, Lamuela-Raventos RM, Joseph JA. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. *Nutr Neurosci*. 2005;8:111-20.
31. Spencer JPE. Flavonoids: modulators of brain function? *Br J Nutr*. 2008;99 E-Suppl 1:ES60-77.
32. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano formulation: the kinetics of tissue distribution and blood-brain barrier penetration. *Int J Pharm*. 2011; 416:331-8.
33. Andres-Lacueva C, Shukitt-Hale B, Galli RL, Jauregui O, Lamuela-Raventos RM, Joseph JA. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. *Nutr Neurosci*. 2005;8:111-20.
34. Passamonti S, Vrhovsek U, Vanzo A, Mattivi F. Fast access of some grape pigments to the brain. *J Agric Food Chem*. 2005;53:7029-34.
35. Kalt W, Blumberg JB, McDonald JE, Vinqvist-Tymchuk MR, Fillmore SA, Graf BA, et al. Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs. *J Agric Food Chem*. 2008;56:705-12.
36. Milbury PE, Kalt W. Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier. *J Agric Food Chem*. 2010;58:3950-6.
37. Dowling DK, Simmons LW. Reactive oxygen species as universal constraints in life-history evolution. *Proc Biol Sci*. 2009;276:1737-45.
38. Valko M, Rhodes CJ, Moncol J, Izacovik M, Mazur M. Free radicals, metals and antioxidants in oxidative stress- induced cancer. *Chem Biol Interact*. 2006;160:1-40.
39. Smith MA, Hiray K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL. Amyloid- $\beta$  deposition in Alzheimer transgenic mice is associated with oxidative stress. *J Neurochem*. 1998;70:2212-5.
40. Gilissen EP, Jacobs RE, Allman JM. Magnetic resonance microscopy of iron in the basal forebrain cholinergic structures of the aged mouse lemur. *J Neurol Sci*. 1999;168:21-7.
41. Savory J, Rao JK, Huang Y. Age-related hippocampal changes in Bcl-2: bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging. *Neurotoxicology*. 1999;20: 805-17.
42. Sadoul R. Bcl-2 family members in the development and degenerative pathologies of the nervous system. *Cell Death Differ*. 1998;5: 805-15.
43. Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, et al. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. *Acta Neuropathol (Berlin)*. 2002;104:113-22.

44. Butterfield DA, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. *Mech Ageing Dev.* 2001;122:945-62.
45. Perez-Campo R, Lopez-Torres MS, Cadenas S. The rate of free radical production as a determinant of the rate of aging: evidence from the comparative approach. *J Comp Physiol.* 1998;168:149-58.
46. Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. *Annu Rev Pharmacol Toxicol.* 1999;39:67-101.
47. Waring P. Redox active calcium ion channels and cell death. *Arch Biochem Biophys.* 2005;434:33-42.
48. Smith CD, Carney JM, Starke-Reed PE. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. *Proc Natl Acad Sci USA.* 1991;88:10540-3.
49. Marcus DL, Thomas C, Rodriguez C. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. *Exp Neurol.* 1998;150:40-4.
50. Dexter DT, Holley AE, Flitter WD. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. *Mov Disord.* 1994;9:92-7.
51. Spencer JP, Jenner P, Daniel SE. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. *J Neurochem.* 1998;71:2112-22.
52. van Acker SA, van den Berg DJ, Tromp MN. Structural aspects of antioxidant activity of flavonoids. *Free Radic Biol Med.* 1996;20:331-42.
53. Perron NR, Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. *Cell Biochem Biophys.* 2009;53:75-100.
54. Mira L, Fernandez MT, Santos M. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. *Free Radic Res.* 2002;36:1199-208.
55. Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and brain health. *Neuromol Med.* 2008;10:259-74.
56. McKeel DW, Price JL, Miller JP, Grant EA, Xiong C, Berg L. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. *J Neuropathol Expe Neurol.* 2004;63:1028-37.
57. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev.* 2001;81:741-66.
58. Bush AI. The metallobiology of Alzheimer's disease. *Trends Neurosci.* 2003;26:207-14.
59. Zhao B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. *Neurochem Res.* 2009;34:630-8.
60. Selkoe DJ. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. *J Alzheimers Dis.* 2001;3:75-80.
61. Sayre LM, Smith MA, Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. *Curr Med Chem.* 2001;8:721-38.
62. Snyder EM, Nong Y, Almeida CG. Regulation of NMDA receptor trafficking by amyloid-beta. *Nat Neurosci.* 2005;8:1051-8.
63. Kishida KT, Klann E. Sources and targets of reactive oxygen species in synaptic plasticity and memory. *Antioxid Redox Signal.* 2007;9:233-44.
64. Kishida KT, Pau M, Holland SM, Klann E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. *J Neurochem.* 2005;94:299-306.
65. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. *J Biol Chem.* 2007;282:11590-601.
66. Shelat PB, Chalimonuik M, Wang JH, Strosznajder JB, Lee JC, Sun AY. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A(2) in cortical neurons. *J Neurochem.* 2008;106:45-55.
67. Sang N, Chen C. Lipid signaling and synaptic plasticity. *Neuroscientist.* 2006;12:425-34.

68. Wang X, Su B, Perry G, Smith MA, Zhu X. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. *Free Radic Biol Med.* 2007;43:1569-73.
69. Butterfield DA, Griffin S, Munch G, Pasinetti GM. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. *J Alzheimers Dis.* 2002;4:193-201.
70. Mancuso C, Scapagini G, Curro D, Stella AMG, De Marco C, Butterfield DA. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. *Front Biosci.* 2007;12:1107-23.
71. Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and Nfkapab- inducing kinase-dependent signaling mechanism. *J Biol Chem.* 2000;275:7918-24.
72. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. *Prog Neurobiol.* 1996;48:1-19.
73. Yang W, Sun AY. Paraquat-induced free radical reaction in mouse brain microsomes. *Neurochem Res.* 1998;23:47-53.
74. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. *Brain Res.* 1999;823:1-10.
75. Halliwall B. Reactive oxygen species and the central nervous system. *J Neurochem.* 1992;59:1609-23.
76. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. *Mol Cell Biochem.* 2010;345:91-104.
77. Eriksen J, Dawson T, Dickson D, Petrucelli L. Caught in the act:  $\alpha$ -synuclein is the culprit in Parkinson's disease. *Neuron.* 2003;40:453-6.
78. Gasser T. Genetics of Parkinson's disease. *J Neurol.* 2001;248:833-40.
79. Cooper AA, Gitler AD, Cashikar A. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science.* 2006;313:324-8.
80. Chinta SJ, Anderson JK. Redox imbalance in Parkinson's disease. *Biochem Biophys Acta.* 2008;1780:1362-7.
81. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. *Ann Neurol.* 1998;44 Suppl 1:S72-84.
82. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. *Science.* 2003; 302:819-22.
83. Riderer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. *J Neurochem.* 1998;52:515-20.
84. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. *J Neurochem.* 2000;74:270-9.
85. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. *Magn Reson Med.* 2005;53:607-13.
86. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. *J Neurosci Res.* 1992;31:327-35.
87. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. *Ann Neurol.* 1992;32:804-12.
88. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. *J Neurol Sci.* 1998;158:47-52.
89. Pinero DJ, Hu J, Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. *Cell Mol Biol (Noisy-Le-Grand).* 2000;46:761-76.
90. Vingtdeux V, Dreses-Werringloer U, Zhau H, Davis P, Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. *BMC Neurosci.* 2008;9 Suppl 2:S6.
91. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. *CNS Neurosci Ther.* 2008;14:352-65.

92. Xu Y, Zhang J, Xiong L, Zhang L, Sun D, Liu H. Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion via modulating oxidative stress. *J Nutr Biochem*. 2010;21:741-8.
93. Graham HN. Green tea composition, consumption, and polyphenol chemistry. *Prev Med*. 1992;21:334-50.
94. Wang ZY, Huang MT, Lou YR, Xie JG, Reuhl KR, Newmark HL, et al. Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. *Cancer Res*. 1994;54:3428-35.
95. Yang CS, Wang ZY. Tea and cancer. *J Natl Cancer Inst*. 1993;85:1038-49.
96. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. *Crit Rev Food Sci Nutr*. 2003;43:89-143.
97. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB. Multifunctional activities of green tea catechins in neuroprotection. *Neurosignals*. 2005;14:46-60.
98. Nanjo F, Mori M, Goto K, Hara Y. Radical scavenging activity of tea catechins and their related compounds. *Biosci Biotechnol Biochem*. 1999;63:1621-3.
99. Deguchi K, Hayashi T, Nagotani S, Sehara Y, Zhang H, Tsuchiya A. Reduction of cerebral infarction in rats by biliverdin associated with amelioration of oxidative stress. *Brain Res*. 2008;1188:1-8.
100. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth Jr WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. *Am J Epidemiol*. 2002;155:732-8.
101. Perron NR, Wang HC, Deguire SN, Jenkins M, Lawson M, Brumaghim JL. Kinetics of iron oxidation upon polyphenol binding. *Dalton Trans*. 2010;39:9982-7.
102. Assunção M, Santos-Marques MJ, Carvalho F, Andrade JP. Green tea averts age-dependent decline of hippocampal signaling systems related to antioxidant defenses and survival. *Free Radic Biol Med*. 2010;48:831-8.
103. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (–)-epigallocatechin-3-gallate prevents *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. *J Neurochem*. 2001;78:1073-82.
104. Pan T, Fei J, Zhou X, Jankovic J, Le W. Effects of green tea polyphenols on dopamine uptake and on MPP<sup>+</sup>-induced dopamine neuron injury. *Life Sci*. 2003;72:1073-83.
105. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. *Nat Struct Mol Biol*. 2008;15:558-66.
106. Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. *Proc Natl Acad Sci USA*. 2010;107:7710-5.
107. Weinreb O, Amit T, Youdim MB. A novel approach of proteomics and transcriptomics to study mechanism of action of the antioxidant-iron chelator green tea polyphenol (–)-epigallocatechin-3-gallate. *Free Radic Biol Med*. 2007;43:546-56.
108. Levites Y, Amit T, Youdim MB, Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (–)-epigallocatechin-3-gallate neuron-protective action. *J Biol Chem*. 2002;277:30574-80.
109. Reznichenko L, Amit T, Youdim MBH, Mandel S. Green tea polyphenol (–)-epigallocatechin-3-gallate induces neurorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. *J Neurochem*. 2005;93:1157-67.
110. Weinreb O, Amit T, Youdim MB. The application of proteomics for studying the neurorescue activity of the polyphenol (–)-epigallocatechin-3-gallate. *Arch Biochem Biophys*. 2008;476:152-60.
111. Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song CW, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. *Brain Res Mol Brain Res*. 2003;118:72-81.
112. Lee SY, Lee JW, Lee H, Yoo HS, Yun YP, Oh KW, et al. Inhibitory effect of green tea extract on beta-amyloid-induced PC12 cell death by inhibition of the activation of NF-kappaB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. *Mol Brain Res*. 2005;140:45-54.
113. Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, et al. The green tea polyphenol (–)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. *Life Sci*. 2001;70:603-14.

114. Joseph JA, Shukitt-Hale B, Lau FC. Fruit polyphenols and their effects on neuronal signaling and behavior in senescence. *Ann NY Acad Sci*. 2007;1100:470-85.
115. Joseph JA, Shukitt-Hale B, Denisova NA, Prior RL, Cao G, Martin A, et al. Long term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. *J Neurosci*. 1998;18:8047-55.
116. Joseph JA, Shukitt-Hale B, Denisova NA, Bielinski D, Martin A, McEwen JJ, et al. Reversals of age-related declines in neuronal signal transduction, cognitive and motor behavioral deficits with blueberry, spinach or strawberry dietary supplementation. *J Neurosci*. 1999;19:8114-21.
117. Gemma C, Mesches MH, Sepesi B, Choo K, Holmes DB, Bickford PC. Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar beta-adrenergic function and increases in proinflammatory cytokines. *J Neurosci*. 2002;22:6114-20.
118. Wang Y, Chang CF, Chou J, Chen HL, Deng X, Harvey BK, et al. Dietary supplementation with blueberries, spinach, or spirulina reduces ischemic brain damage. *Exp Neurol*. 2005;193:75-84.
119. Goyarzu P, Malin DH, Lau FC, Taglialatela G, Moon WD, Jennings R, et al. Blueberry supplemented diet: effects on object recognition memory and nuclear factor-kappa B levels in aged rats. *Nutr Neurosci*. 2004;7:75-83.
120. Mazza G, Kay CD, Cottrell T, Holub BJ. Absorption of anthocyanins from blueberries and serum antioxidant status in human subjects. *J Agric Food Chem*. 2002;50:7731-7.
121. Sweeney MI, Kalt W, Mackinnon SL, Ashby J, Gottschall-Pass KT. Feeding rats diets enriched in lowbush blueberries for six weeks decreases ischemia-induced brain damage. *Nutr Neurosci*. 2002;5:427-31.
122. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, et al. Blueberry supplementation enhanced signaling and prevents behavioral deficits in an Alzheimer's disease model. *Nutr Neurosci*. 2003;6:153-62.
123. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science*. 1997;275:218-20.
124. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? *Clin Biochem*. 1997;30:91-113.
125. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. *Am J Epidemiol*. 2002;156:445-53.
126. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, et al. Renaud, S. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. *Rev Neurol (Paris)*. 1997;153:185-92.
127. Truelsen T, Thudium D, Gronbaek M. Amount and type of alcohol and risk of dementia: the Copenhagen city heart study. *Neurology*. 2002;59:1313-9.
128. Bastianetto S, Brouillette J, Quirion R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. *Neurochem Res*. 2007;32:1720-5.
129. Bastianetto S, Dumont Y, Han Y, Quirion R. Comparative neuroprotective properties of stilbene and catechin analogs: action via a plasma membrane receptor site? *CNS Neurosci Ther*. 2009;15:76-83.
130. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent beta amyloid toxicity through inhibiting NF-kappa B signaling. *J Biol Chem*. 2005;280:40363-74.
131. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappa B is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. *Proc Natl Acad Sci USA*. 1997;94:2642-7.
132. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C. Inhibition of NF-kappa B potentiates amyloid beta-mediated neuronal apoptosis. *Proc Natl Acad Sci USA*. 1999;96:9409-14.
133. Andersen JM, Myhre O, Fonnum F. Discussion of the role of the extracellular signal-regulated kinase-phospholipase A2 pathway in production of reactive oxygen species in Alzheimer's disease. *Neurochem Res*. 2003;28:319-26.
134. Kurzner MS, Xu X. Dietary phytoestrogens. *Annu Rev Nutr*. 1997;17:353-81.

135. Chan WH, Yu JS. Inhibition of UV irradiation-induced oxidative stress and apoptotic biochemical changes in human epidermal carcinoma A431 cells by genistein. *J Cell Biochem.* 2000;78:73-84.
136. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. *J Neurosci Res.* 2004;75:742-50.
137. Ganguli M, Ghandra V, Kamboh MI. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US cross-national dementia study. *Arch Neurol.* 2000;57:824-30.
138. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *J Neurosci.* 2001;21:8370-7.
139. Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE. Curcumin inhibits aggregation of alpha-synuclein. *Acta Neuropathol.* 2008;115:479-89.
140. Baum L, Ng A. Curcumin interactions with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. *J Alzheimers Dis.* 2004;6:367-77.
141. Chen S, Le W. Neuroprotective therapy in Parkinson disease. *Am J Ther.* 2006;13:445-57.
142. Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. *Free Radic Biol Med.* 2008;44:907-17.
143. Ahsan H, Parveen N, Khan NU, Hadi SM. Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. *Chem Biol Interact.* 1999;121:161-75.
144. Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. *Free Radic Biol Med.* 1999;27:544-53.
145. Maitra I, Marcocci L, Droy-Lefaix MT, Packer L. Peroxyl radical scavenging activity of Ginkgo biloba extract EGb 761. *Biochem Pharmacol.* 1995;49:1649-55.
146. Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. *Biochem Biophys Res Commun.* 1994;201:748-55.
147. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. *Proc Natl Acad Sci USA.* 2002;99:12197-202.
148. Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C. *J Neurochem.* 2000;74:2268-77.
149. Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M. Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzheimer's disease. *Cell Mol Biol (Noisy-le-grand).* 2002;48:613-23.
150. Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. *Brain Res.* 2001;889:181-90.
151. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. *Euro J Neurosci.* 2006;12:1882-90.
152. Letenneur L, Proust-Lima C, Le GA. Flavonoid intake and cognitive decline over a 10-year period. *Am J Epidemiol.* 2007;165:1364-71.
153. Spencer JPE. Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neurocognitive performance. *Proc Nutr Soc.* 2008;67:238-52.
154. Shukitt-Hale B, Lau FC, Joseph JA. Berry fruit supplementation and the aging brain. *J Agric Food Chem.* 2008;56:636-41.
155. Shukitt-Hale B, Carey AN, Jenkins D, Rabin BM, Joseph JA. Beneficial effects of fruit extracts of neuronal function and behavior in a rodent model of accelerated aging. *Neurobiol Aging.* 2007;28:1187-94.
156. Wang Y, Wang L, Wu J, Cai J. The *in vivo* synaptic plasticity mechanism of EGb 761-induced enhancement of spatial learning and memory in aged rats. *Br J Pharmacol.* 2006;148:147-53.

157. Joseph JA, Shukitt-Hale B, Denisova NA, Bielinski D, Martin A, McEwen JJ, et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. *J Neurosci.* 1999;19:8114-21.
158. Shif O, Gillette K, Damkaoutis CM, Carrano C, Robbins SJ, Hoffman JR. Effects of *Ginkgo biloba* administered after spatial learning on water maze and radial arm maze performance in young adult rats. *Pharmacol Biochem Behav.* 2006;84:17-25.
159. Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, et al. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. *Neurobiol Dis.* 2006;24:506-15.
160. Winter JC. The effects of an extract of *Ginkgo biloba*, EGb 761, on cognitive behavior and longevity in the rat. *Physiol Behav.* 1998;63:425-33.
161. Hoffman JR, Donato A, Robbins SJ. *Ginkgo biloba* promotes short-term retention of spatial memory in rats. *Pharmacol Biochem Behav.* 2004;77:533-9.
162. Walesiuk A, Trofimiuk E, Braszko JJ. *Ginkgo biloba* normalizes stress- and corticosterone-induced impairment of recall in rats. *Pharmacol Res.* 2006;53:123-8.
163. Ramirez MR, Izquierdo I, Raseira MCB, Zuanazzi JA, Barros D, Henriques AT. Effects of lyophilised *Vaccinium* berries on memory, anxiety and locomotion in adult rats. *Pharmacol Res.* 2005;52:457-62.
164. Pu F, Mishima K, Irie K, Motohashi K, Tanaka Y, Orito K, et al. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. *J Pharmacol Sci.* 2007;104:329-34.
165. Casadesus G, Shukitt-Hale B, Stellwagen HM, Zhu X, Lee H, Smith MA, et al. Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. *Nutr Neurosci.* 2004;7:309-16.
166. van Praag H, Lucero MJ, Yeo GW, Stecker K, Heivand N, Zhao C, et al. Plant derived flavanol (–)-epicatechin enhances angiogenesis and retention of spatial memory in mice. *J Neurosci.* 2007;27:5869-78.
167. Joseph JA, Shukitt-Hale B, Denisova NA, Prior RL, Cao G, Martin A, et al. Long-term dietary strawberry, spinach, or vitamin E supplementation retards the onset of age-related neuronal signal-transduction and cognitive behavioral deficits. *J Neurosci.* 1998;18:8047-55.
168. Shukitt-Hale B, Sheng V, Joseph JA. Effects of blueberries on motor and cognitive function in aged rats. *Nutr Neurosci.* 2009;12:135-40.
169. Andres-Lacueva C, Shukitt-Hale B, Galli RL, Jauregui O, Lamuela-Raventos RM, Joseph JA. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. *Nutr Neurosci.* 2005;8:111-20.
170. Goyarzu P, Malin DH, Lau FC, Taglialatela G, Moon WD, Jennings R, et al. Blueberry supplemented diet: effects on object recognition memory and nuclear factor-kappa B levels in aged rats. *Nutr Neurosci.* 2004;7:75-83.
171. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B, et al. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer's disease model. *Nutr Neurosci.* 2003;6:153-62.
172. Barros D, Amaral OB, Izquierdo I, Geracitano L, Raseira MCB, Henriques AT, et al. Behavioral and genoprotective effects of *Vaccinium* berries intake in mice. *Pharmacol Biochem Behav.* 2006;84:229-34.
173. Willis LM, Shukitt-Hale B, Joseph JA. Recent advances in berry supplementation and age-related cognitive decline. *Curr Opin Clin Nutr Metab Care.* 2009;12:91-4.
174. Neves G, Cooke SF, Bliss TV. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. *Nat Rev Neurosci.* 2008;9:65-75.
175. Bruel-Jungerman E, Davis S, Laroche S. Brain plasticity mechanisms and memory: a party of four. *Neuroscientist.* 2007;13:492-505.
176. Williams SR, Wozny C, Mitchell SJ. The back and forth of dendritic plasticity. *Neuron.* 2007;56:947-53.
177. Howland JG, Wang YT. Synaptic plasticity in learning and memory: stress effects in the hippocampus. *Prog Brain Res.* 2008;169:145-58.
178. Arnsten AF, Ramos BP, Birnbaum SG, Taylor JR. Protein kinase A as a therapeutic target for memory disorders: rationale and challenges. *Trends Mol Med.* 2005;11:121-8.

179. van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: learning to survive. *Prog Neurobiol.* 2006;79:205-21.
180. Alkon DL, Sun MK, Nelson TJ. PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. *Trends Pharmacol Sci.* 2007;28:51-60.
181. Wei F, Qiu CS, Liauw J, Robinson DA, Ho N, Chatila T, Zhuo M. Calcium calmodulin-dependent protein kinase IV is required for fear memory. *Nat Neurosci.* 2002;5:573-9.
182. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. *J Neurochem.* 2001;76:1-10.
183. Sweatt JD. Mitogen-activated protein kinases in synaptic plasticity and memory. *Curr Opin Neurobiol.* 2004;14:311-7.
184. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS, Boss JM, et al. Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. *Cell.* 2004;119:1041-54.
185. Barco A, Bailey CH, Kandel ER. Common molecular mechanisms in explicit and implicit memory. *J Neurochem.* 2006;97:1520-33.
186. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. *Cell.* 1994;79:59-68.
187. Tully T, Bourtchuladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. *Nat Rev Drug Discov.* 2003;2:267-77.
188. Finkbeiner S. CREB couples neurotrophin signals to survival messages. *Neuron.* 2000;25:11-4.
189. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. *Neuron.* 1997;19:1031-47.
190. Thomas K, Davis A. Neurotrophins: a ticket to ride for BDNF. *Curr Biol.* 2005;15:R262-4.
191. Peng S, Wu J, Mufson EJ, Fahnstock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. *J Neurochem.* 2005;93:1412-21.
192. Michalski B, Fahnstock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. *Brain Res Mol Brain Res.* 2003;111:148-54.
193. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell.* 2003;112:257-69.
194. Harris KM, Kater SB. Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function. *Annu Rev Neurosci.* 1994;17:341-71.
195. Alvarez VA, Sabatini BL. Anatomical and physiological plasticity of dendritic spines. *Annu Rev Neurosci.* 2007;30:79-97.
196. Spencer JPE. The interactions of flavonoids within neuronal signalling pathways. *Gen Nutr.* 2007;2:257-73.
197. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. *Science.* 1999;286:1358-62.
198. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol.* 2000;10:381-91.
199. Impey S, Obrietan K, Storm DR. Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. *Neuron.* 1999;23:11-4.
200. Maher P, Akaishi T, Abe K. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. *Proc Natl Acad Sci USA.* 2006;103:16568-73.
201. Schroeter H, Bahia P, Spencer JPE, Sheppard O, Rattray M, Rice-Evans C, et al. (-)Epicatechin stimulates ERK-dependent cyclic AMP response element activity and up-regulates GluR2 in cortical neurons. *J Neurochem.* 2007;101:1596-606.
202. Spencer JPE, Rice-Evans C, Williams RJ. Modulation of pro-survival Akt/Protein Kinase B and ERK1/2 signaling cascades by quercetin and its *in vivo* metabolites underlie their action on neuronal viability. *J Biol Chem.* 2003;278:34783-93.













203. Vauzour D, Vafeiadou K, Rice-Evans C, Williams RJ, Spencer JPE. Activation of pro-survival Akt and ERK1/2 signalling pathways underlie the anti-apoptotic effects of flavanones in cortical neurons. *J Neurochem.* 2007;2:1355-67.
204. Levites Y, Amit T, Youdim MB, Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (–)-epigallocatechin 3-gallate neuroprotective action. *J Biol Chem.* 2002;277:30574-80.
205. Agullo G, Gamet-Payraastre S, Manenti S, Viala C, Remesy C, Chap H, Payraastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. *Biochem Pharmacol.* 1997;53:1649-57.
206. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. *Mol Cell.* 2000;6:909-19.
207. Williams CM, El Mohsen MA, Vauzour D, Rendeiro C, Butler LT, Ellis JA, et al. Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. *Free Radic Biol Med.* 2008;45:295-305.
208. Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido Y. Long term administration of green tea catechins improves spatial cognition learning ability in rats. *J Nutr.* 2006;136:1043-7.
209. Schrott GM, Nigh EA, Chen WG, Hu L, Greenberg ME. BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal development. *J Neurosci.* 2004;24:7366-77.
210. Yin Y, Edelman GM, Vanderklish PW. The brain-derived neurotrophic factor enhances synthesis of Arc in synaptoneurosome. *Proc Natl Acad Sci USA.* 2002;99:2368-73.
211. Waltereit R, Dammermann P, Wulff P, Scafidi U, Staubli U, Kauselmann G, et al. Arg3.1/Arc mRNA induction by Ca<sup>2+</sup> and cAMP requires protein kinase A and mitogen-activated protein kinase/extracellular regulated kinase activation. *J Neurosci.* 2001;21:5484-93.
212. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein is enriched in neuronal dendrites. *Neuron.* 1995;14:433-45.
213. Nagase H, Yamakuni T, Matsuzaki K, Maruyama Y, Kasahara J, Hinohara Y, et al. Mechanism of neurotrophic action of nobiletin in PC12D cells. *Biochemistry.* 2005;44:13683-91.
214. Matsuzaki K, Miyazaki K, Sakai S, Yawo H, Nakata N, Moriguchi S, et al. Nobiletin, a citrus flavonoid with neurotrophic action, augments protein kinase A-mediated phosphorylation of the AMPA receptor subunit, GluR1, and the postsynaptic receptor response to glutamate in murine hippocampus. *Eur J Pharmacol.* 2008;578:194-200.
215. Al RM, Nakajima A, Saigusa D, Tetsu N, Maruyama Y, Shybuya M, et al. 4'-Demethylnobiletin, a bioactive metabolite of nobiletin enhancing PKA/ERK/CREB signaling, rescues learning impairment associated with NMDA receptor antagonism via stimulation of the ERK cascade. *Biochemistry.* 2009;48:7713-21.
216. Nagahama Y, Nabatame H, Okina T, Yamauchi H, Narita M, Fujimoto N, et al. Cerebral correlates of the progression rate of the cognitive decline in probable Alzheimer's disease. *Eur Neurol.* 2003;50:1-9.
217. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. *Ann Neurol.* 2005;57:789-94.
218. Spencer JPE. The impact of fruit flavonoids on memory and cognition. *Br J Nutr.* 2010;104 Suppl:S40-7.
219. Schroeter H, Heiss H, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. (–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Natl Acad Sci USA.* 2006;103:1024-9.
220. Heiss C, Schroeter J, Balzer J, Kleinbongard P, Matern S, Sies H, et al. Endothelial function, nitric oxide, and cocoa flavanols. *J Cardiovasc Pharmacol.* 2006;47 Suppl 2:S128-35.
221. Gage FH. Mammalian neural stem cells. *Science.* 2000;287:1433-8.
222. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. *J Comp Neurol.* 2000;425:479-94.
223. Francis ST, Head K, Morris PG, Macdonald IA. The effect of flavanol-rich cocoa on the fMRI response to a cognitive task in healthy young people. *J Cardiovasc Pharmacol.* 2006;47 Suppl 2:S215-20.


224. Fisher ND, Sorond FA, Hollenberg NK. Cocoa flavanols and brain perfusion. *J Cardiovasc Pharmacol*. 2006;47 Suppl 2:S210-4.
225. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. *Parkinsonism Relat Disord*. 2005;11 Suppl:S9-15.
226. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. *Prog Neuropsychopharmacol Biol Psychiatry*. 2003;27:741-9.
227. Zheng Z, Lee JE, Yenari MA. Stroke: molecular mechanism and potential targets for treatment. *Curr Mol Med*. 2003;3:361-72.
228. Casper D, Yaparpalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. *Neurosci Lett*. 2000;289:201-4.
229. Chen H, Zhang SM, Herman MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's disease. *Arch Neurol*. 2003;60:1059-64.
230. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer's disease. *Neurology*. 2008;70:1672-7.
231. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. *Trends Neurosci*. 1996;19:312-8.
232. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. *Parkinsonism Relat Disord*. 2004;10:S3-S7.
233. Lutermaier JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. *Arch Neurol*. 2000;57:1153-60.
234. Tarkowski E, Liljeroth L, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. *Brain Res Bull*. 2003;61:255-60.
235. Chen S, Frederickson RC, Brunden KR. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. *Neurobiol Aging*. 1996;17:781-7.
236. Vauzour D, Vafeiadou K, Rodriguez-Mateos A, Rendeiro C, Spencer JPE. The neuroprotective potential of flavonoids: a multiplicity of effects. *Genes Nutr*. 2008;3:115-6.
237. Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. *Free Radic Biol Med*. 2004;37:304-17.
238. Spencer JPE, Vafeiadou K, Williams RJ, Vauzour D. Neuroinflammation: modulation by flavonoids and mechanisms of action. *Mol Asp Med*. 2012;33:83-97.
239. Levites Y, Youdim MB, Maor G, Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. *Biochem Pharmacol*. 2002;63:21-9.
240. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenols (–)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. *J Neurochem*. 2001;78:1073-82.
241. Lee S, Suh S, Kim S. Protective effects of the green tea polyphenol (–)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. *Neurosci Lett*. 2000;287:191-4.
242. Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). *J Alzheimers Dis*. 2008;15:211-22.
243. Mandel SA, Abramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, et al. Multifunctional activities of green tea catechins in neuroprotection: modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. *Neurosignals*. 2005;14:46-60.
244. Mandel S, Weinreb O, Amit T, Youdim MB. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (–)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. *J Neurochem*. 2004;88:1555-69.
245. Mandel S, Reznichenko L, Amit T, Youdim MB. Green tea polyphenol (–)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. *Neurotox Res*. 2003;5:419-24.

246. Vauzour D, Vafeiadou K, Spencer JPE. Inhibition of the formation of the neurotoxin 5-S-cysteinyl-dopamine by polyphenols. *Biochem Biophys Res Commun.* 2007;362:340-6.
247. Spencer JPE, Jenner P, Daniel SE, Lees AJ, Marsden DC, Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. *J Neurochem.* 1998;71:2112-22.
248. Spencer JPE, Whiteman M, Jenner P, Halliwell B. 5-S-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. *J Neurochem.* 2002;81:122-9.
249. Vauzour D, Ravaoli G, Vafeiadou K, Rodriguez-Mateos A, Angeloni C, Spencer JPE. Peroxynitrite induced formation of the neurotoxins 5-S-cysteinyl-dopamine and DHBT-1: implications for Parkinson's disease and protection by polyphenols. *Arch Biochem Biophys.* 2008;476:145-51.
250. Vafeiadou K, Vauzour D, Lee HY, Rodriguez-Mateos A, Williams RJ, Spencer JPE. The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. *Arch Biochem Biophys.* 2009;484:100-9.
251. Lau FC, Bielinski DF, Joseph JA. Inhibitory effects of blueberry extract on the production of inflammatory mediators in lipopolysaccharide-activated BV2 microglia. *J Neurosci Res.* 2007;85:1010-7.
252. Chen JC, Ho FM, Pei-Dawn LC, Chen CP, Jeng KCG, Hsu HB, et al. Inhibition of iNOS gene expression by quercetin is mediated by the inhibition of I $\kappa$ B kinase, nuclear factor-kappa B and STAT1, and depends on heme oxygenase-1 induction in mouse BV-2 microglia. *Eur J Pharmacol.* 2005;521: 9-20.
253. Li R, Huang YG, Fang D, Le WD. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. *J Neurosci.* 2004;78:723-31.
254. Williams RJ, Spencer JPE. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. *Free Radic Biol Med.* 2012;52:35-45.
255. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. *Biochem Pharmacol.* 2006;72:1439-52.
256. Owuor ED, Kong AN. Antioxidants and oxidants regulated signal transduction pathways. *Biochem Pharmacol.* 2002;64:765-70.

**Table 1** – Chemical structures of main groups of polyphenols.


Polyphenols	Flavonoid	Flavonols		R1=H; R2=OH; R3=H: kaempferol R1=OH; R2=OH; R3=H: quercetin R1=OH; R2=OH; R3=OH: myricetin
		Flavan-3-ols	 Monomeric	R1=H; R2=OH; R3=H: (+)-catechin R1=OH; R2=H; R3=H: (-)-epicatechin R1=OH; R2=OH; R3=OH: (+)-gallocatechin
		Flavones		R1=H; R2=OH: apigenin R1=OH; R2=OH: luteolin
		Flavanones		R1=H; R2=H; R3=OH: naringenin R1=OH; R2=OH; R3=OMe: hesperetin
		Isoflavones		R1=H: daidzein R2=OH: genistein
		Anthocyanidins		R1=H; R2=H: pelargonidin R1=OH; R2=H: cyanidin R1=OH; R2=OH: delphinidin R1=OMe; R2=OH: petunidin R1=OMe; R2=OMe: malvidin
	Non-flavonoid	Phenolic acids	 Hydroxycinnamic acids	R1=H; R2=OH: <i>p</i> -coumaric acid R1=OH; R2=OH: caffeic acid R1=OMe; R2=OH: ferulic acid
			 Hydroxybenzoic acids	R1=OH; R2=OH; R3=H: protocatechuic acid R1=OH; R2=OH; R3=OH: gallic acid
		Stilbenes		resveratrol
		Lignans		secoisolariciresinol

## Effects of polyphenols on memory, learning and cognition.



**Figure 1.** Polyphenol-induced activation of neuronal signalling and gene expression in the brain, may lead to changes in synaptic plasticity and neurogenesis in the brain which ultimately influence memory, learning and cognition. Adapted from Spencer JPE (Ref. 218).

## Effects of polyphenols on neurodegeneration and brain ageing.



**Figure 2.** The polyphenol-induced inhibition of pro-apoptotic signalling in neurons, and reduction of neuroinflammatory reactions in microglia, may prevent neurodegeneration and brain ageing. Adapted from Spencer JPE. (Ref. 218).